CN105232592B - A kind of pharmaceutical composition and its application for treating malignant lymphoma - Google Patents
A kind of pharmaceutical composition and its application for treating malignant lymphoma Download PDFInfo
- Publication number
- CN105232592B CN105232592B CN201510675296.1A CN201510675296A CN105232592B CN 105232592 B CN105232592 B CN 105232592B CN 201510675296 A CN201510675296 A CN 201510675296A CN 105232592 B CN105232592 B CN 105232592B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- malignant lymphoma
- parts
- prepared
- balansae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition and its application for treating malignant lymphoma, which is prepared by the traditional Chinese medicinal material raw materials of following parts by weight through precipitating obtained by water extraction and alcohol precipitation method: 28-40 parts of Cyrtomium balansae (Christ) C. Chr, 52-70 parts of lotus root.Pharmaceutical composition of the invention significantly inhibits the growth of malignant lymphom cells, while the Chinese medicine wide, inexpensive, that toxic side effect is low in origin source is prepared, and can be developed into the Chinese patent medicine preparation for the treatment of malignant lymphoma.
Description
Technical field
The invention belongs to technical field of Chinese medicine, in particular to a kind of pharmaceutical composition for treating malignant lymphoma
And application thereof.
Background technique
Malignant lymphoma is to be primary in the malignant tumour of lymph node or other lymphoid tissues.In China, lymthoma is all
Disease incidence rises most fast in malignant tumour, and annual 5% speed rises, occupied the big malignant tumour of disease incidence highest ten it
One.According to statistics, about 8.4 ten thousand people of Lymphoma is newly sent out in China every year, and death toll is more than 4.7 ten thousand, and morbidity crowd is young
Change and urbanization trend increasingly aggravates.It is more common in the young and the middle aged, male patient is more than women.
Malignant lymphoma is with a quite heterogeneous major class tumour, although being apt to occur in lymph node, due to lymph
The characteristic distributions of system can almost invade any tissue of whole body and organ so that lymthoma belongs to systemic disease.Cause
This, the clinical manifestation of malignant lymphoma had both had certain common feature, while according to different histological types, invaded position and
There is very big differences again for range.There are round or similar round or lobulated shade, lesion growth that can oppress branch on C-XF
Tracheae causes atelectasis, and center of tumor necrosis sometimes forms cavity.Some pulmonary lesions show as diffusivity interstitial and sexually revise, at this time
Clinical symptoms are obvious, often there is cough, expectoration, shortness of breath, expiratory dyspnea, and secondary infection can have fever；Malignant lymphoma can invade the heart
Flesh and pericardium show as hydropericardium, and lymthoma invades cardiac muscle and shows as Myocardial damage, can there is cardiac arrhythmia, electrocardiographic abnormality
Deng performance；It is to be invaded position under the most common diaphragm of HL that abdomen, which shows spleen,.Gastrointestinal tract is then the outer diseased region of the most common knot of NHL.
After mesenterium, peritonaeum and iliac fossa lymph node etc. is also the common infringement position of lymthoma；Cutaneous manifestations malignant lymphoma can it is primary or
Secondary skin is invaded, and NHL is more common in；The bone marrow involvement of marrow malignant lymphoma shows as marrow and is invaded or merged leukaemia, more
Belong to one of terminal stage of a disease performance, the overwhelming majority is NHL；Manifestations of nervous system, such as the multifocal leukoencephalopathy of progressive, subacute bad
Extremely other performances of property myelopathy, feeling or motility peripheral neuropathy and multiple myopathy etc..Malignant lymphoma can be with
It is primary or secondary to after brain, epidural, testis, ovary, vagina, uterine neck, mammary gland, thyroid gland, adrenal gland, eye socket ball tissue,
Larynx, bone and muscular soft tissues etc., complicated clinical manifestation multiplicity.
Although hematopoietic stem cell transplantation or molecular targeted drug therapy malignant lymphoma obtain preferable achievement (Glass B,
Kfo ess M,Bentz M,et al.Dose-escalated CH OP plus eto po side(Mega CH OEP)
followed by r epeated stem cell transplant-tation fo r prima ry t reatment o
f ag g ressive high-r isk no n-H odg kin lymphoma[J].Blo od,2006,107(8):3058-
3064.), but due to being influenced by factors such as idicatio and medical expenses, conventional chemotherapy is still current mainly to control
Treatment means.However, almost existing chemotherapeutics has bone marrow suppression, alopecia, gastrointestinal reaction, hepatic and renal function damage etc. secondary anti-
It answers, only occurrence degree is different with face is stressed.Therefore, the small anti-lymphadenoma drug of new toxic side effect is researched and developed with important
Meaning.In exploratory development of the mankind to anticancer drug, Chinese medicine, crude drug increasingly highlighted its drug effect it is good, without it is additive,
Adverse reaction is few and the advantages such as resourceful, attracts people's attention.Therefore, it finds and develops a kind of prevention and treatment malignant lymphoma
Chinese Traditional Medicines, this is particularly important.
Summary of the invention
It is an object of the invention to provide a kind of medicine for treating malignant lymphoma by furtheing investigate to folk remedy
Object, the drug have ideal bioactivity in terms of inhibiting lymphoma cell proliferation.
The object of the present invention is achieved like this:
A kind of pharmaceutical composition for treating malignant lymphoma, the pharmaceutical composition are former by the Chinese medicine of following parts by weight
Material is prepared through precipitating obtained by water extraction and alcohol precipitation method: 28-40 parts of Cyrtomium balansae (Christ) C. Chr, 52-70 parts of lotus root.
It is further preferred that the pharmaceutical composition for the treatment of malignant lymphoma is former by the Chinese medicine of following parts by weight as described above
Material is prepared through precipitating obtained by water extraction and alcohol precipitation method: 32-35 parts of Cyrtomium balansae (Christ) C. Chr, 58-63 parts of lotus root.
Still further preferably, the pharmaceutical composition of malignant lymphoma is treated as described above by the Chinese medicine of following parts by weight
Raw material is prepared through precipitating obtained by water extraction and alcohol precipitation method: 33 parts of Cyrtomium balansae (Christ) C. Chr, 60 parts of lotus root.
It should be noted that in the pharmaceutical composition for preparing treatment malignant lymphoma of the present invention, Chinese medicine therein
The dry root of material raw material lotus root selection malvaceae plant cotton rose Hibiscus mutabilis L..
Pharmaceutical composition of the present invention the preparation method comprises the following steps: weigh 28-40 parts of Cyrtomium balansae (Christ) C. Chr, 52-70 parts of lotus root, merge powder
It is broken；Add water to cover powder above-mentioned graininess medicinal material again to impregnate 0.2-1.0h, then pull out and be placed in extraction element, add water to cook
1-4 times, each amount of water is 10-20 times of medicinal material total amount, boils by intense fire and is cooked by slow fire 1-3h, is filtered, and filtrate decompression is concentrated into
Relative density is 0.9-1.2, and ethyl alcohol is added to make volume alcohol content up to 73-77%, and stirring, standing makes sufficiently to precipitate, and filters, and gained is heavy
It forms sediment after drying to obtain the final product.
Pharmaceutical composition of the invention is prepared using water extract-alcohol precipitation hair, i.e., precipitating obtained by water extraction and alcohol precipitation method is prepared
Chinese medical extract B；And that filtrate obtained by water extraction and alcohol precipitation method is prepared is Chinese medical extract A.The present inventor leads to cell in vitro
Experimental study discovery, Chinese medical extract A do not have an obvious inhibiting effect to Raji cell in-vitro growth, and B pairs of Chinese medical extract
Raji cell in-vitro is with obvious inhibiting effect, m- dose-dependence when inhibiting rate is in, i.e., under same concentrations, with
Drug treating time extend, inhibiting rate significantly increases.In addition, under identical drug concentration, the inhibiting rate of Chinese medical extract B group
Significantly it is higher than Chinese medical extract A group, difference is statistically significant (P < 0.01).Therefore, it is another object of the present invention to
There is provided a kind of pharmaceutical applications, it may be assumed that the feedstock composition of Cyrtomium balansae (Christ) C. Chr and lotus root composition is through being deposited in system obtained by water extraction and alcohol precipitation method
Purposes in the drug of standby treatment malignant lymphoma.
Compared with prior art, pharmaceutical composition of the invention has apparent inhibit to the growth of malignant lymphom cells
Effect, while the Chinese medicine wide, inexpensive, that toxic side effect is low in origin source is prepared, it is expected to exploitation is at treatment malignant lymphoma
Chinese patent medicine preparation.
Specific embodiment
Preparation embodiment and effete test embodiment of the invention below, to technical solution of the present invention and technical effect do into
The explanation of one step.It should be noted that traditional Chinese medicinal material raw materials used in the embodiment of the present invention have following source: Cyrtomium balansae (Christ) C. Chr is selected
Dryopteridaceae plant Cyrtomium balansae (Christ) C. Chr Cyrtomium balansae (Christ) C.Chr. [Polypodium balansae
Christ] dry rhizome.The dry root of lotus root selection malvaceae plant cotton rose Hibiscus mutabilis L..
The preparation of 1 Chinese medical extract of embodiment
Cyrtomium balansae (Christ) C. Chr 3.3kg, lotus root 6.0kg are weighed, merges and crushes；Water is added to cover powder above-mentioned graininess medicinal material again
2cm impregnates 0.5h, then pulls out and be placed in extraction element, adds water to cook 3 times, the 1st time plus water 130L, boils by intense fire and be cooked by slow fire
2h is boiled, the 2nd time plus water 120L, boils by intense fire and is cooked by slow fire 1.5h, the 3rd time plus water 120L, boils by intense fire and is cooked by slow fire 1.5h, is closed
And decocting liquid, filtering, it is 1.10 (65 DEG C of surveys) that filtrate is concentrated under reduced pressure into relative density under conditions of 0.08MPa, adds 95% ethyl alcohol
Make volume alcohol content up to 75% or so, stirring, standing 48 hours makes sufficiently to precipitate, and filters, gained filtrate is under the conditions of 0.08MPa
Ethyl alcohol is recovered under reduced pressure and is concentrated into thick paste, is freeze-dried, crushing sieves with 100 mesh sieve, and obtains Chinese medical extract dry powder A；Gained precipitating
Freeze-drying, crushing sieve with 100 mesh sieve, and obtain Chinese medical extract dry powder B.
2 Chinese medical extract of embodiment studies the growth inhibition test of malignant lymphoma Raji cells in vitro
People's malignant lymphoma Raji cell of logarithmic growth phase adjusts concentration to 1.5 × 105The cell suspension of/mL, connects
Kind is in 96 orifice plates of the RPMI1640 culture medium containing 10% fetal calf serum, and every hole is inoculated with 90 μ L, and every group sets 4 multiple holes.37℃,
5%CO2Cultivate 12h in incubator, cell is divided into negative control group and experimental group: any drug is not added in negative control group, real
Test group Chinese medical extract dry powder A, a B that various concentration is added, 10 holes μ L/.48,72h are cultivated respectively after each group dosing, are added
10 hole μ L/ M TT of 5g/L continues to cultivate 4h, and three liquid (10% SDS, 5% isobutanol, 0.012mol/L is added in every hole
Hydrochloric acid) 100 μ L termination reaction, in 37 DEG C of placement 12h, microplate reader measures the absorbance value (OD value) that wavelength is 492nm, takes each group
Mean value repeats experiment 3 times.Growth inhibition ratio: inhibiting rate (%)=(negative control group OD value-experiment is calculated with following formula
Group OD value)/negative control group OD value × 100%.
It can be seen that Chinese medical extract A by the test statistics result of table 1 obviously not press down Raji cell in-vitro growth
Production use, and Chinese medical extract B to Raji cell in-vitro with obvious inhibiting effect, m- dose-dependant when inhibiting rate is in
Relationship, i.e., under same concentrations, as drug treating time extends, inhibiting rate significantly increases.In addition, in identical drug concentration
Under, the inhibiting rate of Chinese medical extract B group is significantly higher than Chinese medical extract A group, and difference is statistically significant (P < 0.01), sees
Table 1.
The different Chinese medical extracts of table 1 compare (%) to the inhibiting rate of Raji cell proliferation in vitro
Under the identical drug concentration of same time, Chinese medical extract B group compared with Chinese medical extract A group,*P < 0.01.
Claims (3)
1. a kind of pharmaceutical composition for treating malignant lymphoma, it is characterised in that the pharmaceutical composition is by following parts by weight
Traditional Chinese medicinal material raw materials are prepared through precipitating obtained by water extraction and alcohol precipitation method: 32-35 parts of Cyrtomium balansae (Christ) C. Chr, 58-63 parts of lotus root.
2. the pharmaceutical composition for the treatment of malignant lymphoma according to claim 1, it is characterised in that the pharmaceutical composition
Object is prepared by the traditional Chinese medicinal material raw materials of following parts by weight through precipitating obtained by water extraction and alcohol precipitation method: 33 parts of Cyrtomium balansae (Christ) C. Chr, lotus root 60
Part.
3. the pharmaceutical composition for the treatment of malignant lymphoma according to claim 1 or 2, it is characterised in that: the Chinese medicine
The dry root of material raw material lotus root selection malvaceae plant cotton rose Hibiscus mutabilis L..
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675296.1A CN105232592B (en) | 2015-10-16 | 2015-10-16 | A kind of pharmaceutical composition and its application for treating malignant lymphoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675296.1A CN105232592B (en) | 2015-10-16 | 2015-10-16 | A kind of pharmaceutical composition and its application for treating malignant lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105232592A CN105232592A (en) | 2016-01-13 |
| CN105232592B true CN105232592B (en) | 2019-02-15 |
Family
ID=55030591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510675296.1A Expired - Fee Related CN105232592B (en) | 2015-10-16 | 2015-10-16 | A kind of pharmaceutical composition and its application for treating malignant lymphoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232592B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327309A (en) * | 2007-06-21 | 2008-12-24 | 尧抚人 | Chinese medicine for treating lymph cancer, nasopharyngeal carcinoma and brain cancer |
| CN104825583A (en) * | 2015-05-20 | 2015-08-12 | 陈菊元 | Traditional Chinese medicine dressing for eliminating lymphoma |
-
2015
- 2015-10-16 CN CN201510675296.1A patent/CN105232592B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327309A (en) * | 2007-06-21 | 2008-12-24 | 尧抚人 | Chinese medicine for treating lymph cancer, nasopharyngeal carcinoma and brain cancer |
| CN104825583A (en) * | 2015-05-20 | 2015-08-12 | 陈菊元 | Traditional Chinese medicine dressing for eliminating lymphoma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105232592A (en) | 2016-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103190504B (en) | Method for processing peony pistil tea | |
| CN103355556A (en) | Corn type mixed feed for weaned pig and preparation method thereof | |
| CN104054972A (en) | Feed for raising river crab | |
| CN105816430B (en) | A kind of preparation method with antitumor action radix tetrastigme polyoses grain | |
| Welch et al. | Investigation of Moringa oleifera leaf extract and its cancer-selective antiproliferative properties | |
| CN109123032A (en) | Composition and preparation process with warm kidney yang-tonifying warm kidney benefiting yin function of promoting longevity | |
| CN104800174A (en) | Raspberry polysaccharide lozenges and applications thereof | |
| CN102488198A (en) | Antioxidant health food preparation for protecting cardiovascular system and its preparation method | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN105232592B (en) | A kind of pharmaceutical composition and its application for treating malignant lymphoma | |
| CN106389535A (en) | Application of industrial hemp cannaboid in preparing gout treating medicines | |
| CN103142916A (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| CN105030858A (en) | Cynomorium songaricum healthcare tablet and preparation method thereof | |
| CN108853469A (en) | Improve the composition and preparation process of mankind spermatozoon vigor and male erection function | |
| CN106072569B (en) | The special dietary seafood of patient's immunocyte balance is adjusted during a kind of chemicotherapy | |
| CN108938677A (en) | A kind of Sargassum polycystum extract and the preparation method and application thereof with treatment breast cancer effect | |
| CN108208781A (en) | A kind of reparation hepatic injury, the Cordyceps militaris composition and preparation method and application of strengthen immunity | |
| CN109043527A (en) | It adjusts human-body sub-health and improves the composition and preparation process of immunity | |
| CN103845581A (en) | Natural green composition and application thereof to preventing and treating diabetes | |
| CN109010788A (en) | Improve the composition and preparation process of sleep and urine urgency-frequency night pollakiuria disease | |
| Momin et al. | Determination of lipid and alkaloid content in some medicinal plants of genus Sesbania | |
| CN103655648B (en) | The preparation method of little leaf boxwood active component and purposes | |
| CN103484383B (en) | Method for producing hirsutella sinensis with solids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190215 Termination date: 20211016 |